1
|
Bouchmaa N, Ben Mrid R, Bouargalne Y, Ajouaoi S, Cacciola F, El Fatimy R, Nhiri M, Zyad A. In vitro evaluation of dioscin and protodioscin against ER-positive and triple-negative breast cancer. PLoS One 2023; 18:e0272781. [PMID: 36757991 PMCID: PMC9910703 DOI: 10.1371/journal.pone.0272781] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2022] [Accepted: 07/26/2022] [Indexed: 02/10/2023] Open
Abstract
Women's breast cancer is one of the most significant healthcare issues for the human race that demands a proactive strategy for a cure. In this study, the cytotoxic activity (MTT assay) of two natural steroidal compounds, protodioscin and dioscin, against two major subtypes of human breast cancer estrogen receptor-positive (ER-positive)/MCF-7 and triple-negative breast cancer (TNBC)/MDA-MB-468), was assessed. The clonogenic capacity was evaluated using the clonogenic assay. Oxidative stress was determined by measuring the formation of malondialdehyde and H2O2 and the assessment of total antioxidant enzyme activities (SOD, GPx, GR, and TrxR). Protodioscin and dioscin were highly cytotoxic against the tested cell lines (1.53 μM <IC50< 6 μM) with low cytotoxicity on normal cells (PBMC; IC50 ≥ 50 μM). Interestingly, these compounds were responsible for a substantial decrease in the clonogenic capacity of both cell lines. Moreover, dioscin was able to reduce the cell motility of the invasive breast cancer cells (MDA-MB-468). At the molecular level, the two treatments resulted in an increase of reactive oxygen species. Notably, both compounds were responsible for decreasing the enzymatic activities of glutathione reductase and thioredoxin reductase. On the basis of such considerations, protodioscin and dioscin may serve as promising natural compounds to treat TNBC and ER-positive breast cancer through the induction of oxidative stress.
Collapse
Affiliation(s)
- Najat Bouchmaa
- Faculty of Science and Technology, Team of Experimental Oncology and Natural Substances, Cellular and Molecular Immuno-Pharmacology, Sultan Moulay Slimane University, Beni-Mellal, Morocco
- Institute of Medical and Biological Sciences, Mohammed VI Polytechnic University (UM6P), Ben-Guerir, Morocco
- * E-mail: (NB); (AZ)
| | - Reda Ben Mrid
- Institute of Medical and Biological Sciences, Mohammed VI Polytechnic University (UM6P), Ben-Guerir, Morocco
- Faculty of Science and Technology, Laboratory of Biochemistry and Molecular Genetics, Abdelmalek Essaadi University, Tangier, Morocco
| | - Youssef Bouargalne
- Faculty of Science and Technology, Laboratory of Biochemistry and Molecular Genetics, Abdelmalek Essaadi University, Tangier, Morocco
| | - Sana Ajouaoi
- Faculty of Science and Technology, Team of Experimental Oncology and Natural Substances, Cellular and Molecular Immuno-Pharmacology, Sultan Moulay Slimane University, Beni-Mellal, Morocco
| | - Francesco Cacciola
- Department of Biomedical, Dental, Morphological and Functional Imaging Sciences, University of Messina, Messina, Italy
| | - Rachid El Fatimy
- Institute of Medical and Biological Sciences, Mohammed VI Polytechnic University (UM6P), Ben-Guerir, Morocco
| | - Mohamed Nhiri
- Faculty of Science and Technology, Laboratory of Biochemistry and Molecular Genetics, Abdelmalek Essaadi University, Tangier, Morocco
| | - Abdelmajid Zyad
- Faculty of Science and Technology, Team of Experimental Oncology and Natural Substances, Cellular and Molecular Immuno-Pharmacology, Sultan Moulay Slimane University, Beni-Mellal, Morocco
- * E-mail: (NB); (AZ)
| |
Collapse
|
2
|
Yin J, Lin Y, Fang W, Zhang X, Wei J, Hu G, Liu P, Niu J, Guo J, Zhen Y, Li J. Tetrandrine Citrate Suppresses Breast Cancer via Depletion of Glutathione Peroxidase 4 and Activation of Nuclear Receptor Coactivator 4-Mediated Ferritinophagy. Front Pharmacol 2022; 13:820593. [PMID: 35614944 PMCID: PMC9124810 DOI: 10.3389/fphar.2022.820593] [Citation(s) in RCA: 14] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2022] [Accepted: 04/06/2022] [Indexed: 01/25/2023] Open
Abstract
Tetrandrine citrate (TetC), a novel tetrandrine salt with high water solubility, demonstrates a potent antitumor activity in chronic myeloid leukemia. Studies have indicated an important role of ferroptosis in breast cancer (BC). However, whether TetC inhibits BC progression via ferroptosis has never been explored. In the present study, we showed that TetC had a significant inhibitory effect on the proliferation and migration of MCF7 and MDA-MB-231 cells. Then, we combined TetC with different inhibitors to determine which form of cell death could be driven by TetC. MTT assay showed that ferrostatin (Fer-1) demonstrated the most potent effect on improving TetC-induced cell death in contrast to other inhibitors. TetC was also shown to significantly increase the mRNA level of prostaglandin-endoperoxide synthase 2 (Ptgs2), a ferroptosis marker. Further studies showed that TetC significantly suppressed the expression of glutathione peroxidase 4 (GPX4) and ferritin heavy chain 1 (FTH1) but increased the expression of nuclear receptor coactivator 4 (NCOA4) in MCF7 and MDA-MB-231 cells even in the presence of erastin or Ras-selective lethal 3 (RSL3). Collectively, we showed novel data that ferroptosis was a major form of TetC-induced cell death. Moreover, TetC-induced ferroptotic cell death was achieved via suppressing GPX4 expression and activating NCOA4-mediated ferritinophagy in BC cells.
Collapse
Affiliation(s)
- Jiameng Yin
- Hebei Key Laboratory for Chronic Diseases, School of Basic Medical Sciences, North China University of Science and Technology, Tangshan, China
- The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Institue of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology of National Health Commission, Beijing, China
| | - Yajun Lin
- The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Institue of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology of National Health Commission, Beijing, China
| | - Weiwei Fang
- State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Department of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Xin Zhang
- The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Institue of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology of National Health Commission, Beijing, China
| | - Jie Wei
- The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Institue of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology of National Health Commission, Beijing, China
| | - Gang Hu
- The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Institue of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology of National Health Commission, Beijing, China
| | - Pu Liu
- The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Institue of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology of National Health Commission, Beijing, China
| | - Jie Niu
- The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Institue of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology of National Health Commission, Beijing, China
| | - Jun Guo
- The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Institue of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology of National Health Commission, Beijing, China
- *Correspondence: Jun Guo, ; Yongzhan Zhen, ; Jian Li,
| | - Yongzhan Zhen
- Hebei Key Laboratory for Chronic Diseases, School of Basic Medical Sciences, North China University of Science and Technology, Tangshan, China
- *Correspondence: Jun Guo, ; Yongzhan Zhen, ; Jian Li,
| | - Jian Li
- The Key Laboratory of Geriatrics, Beijing Institute of Geriatrics, Institue of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing Hospital/National Center of Gerontology of National Health Commission, Beijing, China
- *Correspondence: Jun Guo, ; Yongzhan Zhen, ; Jian Li,
| |
Collapse
|